Unknown

Dataset Information

0

A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.

ABSTRACT: UNLABELLED:The ideal dengue vaccine will provide protection against all serotypes of dengue virus and will be economical and uncomplicated in its administration. To determine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to induce a suitable neutralizing antibody response, a placebo-controlled clinical trial was performed in 48 healthy adults who received 2 doses of vaccine or placebo administered 12 months apart. Evaluation of safety, vaccine viremia, and neutralizing antibody response after each dose indicated that the first dose of vaccine was capable of preventing infection with the second dose, thus indicating that multiple doses are unnecessary. CLINICAL TRIALS REGISTRATION:NCT01782300.

SUBMITTER: Durbin AP 

PROVIDER: S-EPMC4996143 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.

Durbin Anna P AP   Kirkpatrick Beth D BD   Pierce Kristen K KK   Carmolli Marya P MP   Tibery Cecilia M CM   Grier Palmtama L PL   Hynes Noreen N   Opert Kari K   Jarvis Adrienne P AP   Sabundayo Beulah P BP   McElvany Benjamin D BD   Sendra Eli A EA   Larsson Catherine J CJ   Jo Matthew M   Lovchik Janece M JM   Luke Catherine J CJ   Walsh Mary C MC   Fraser Ellen A EA   Subbarao Kanta K   Whitehead Stephen S SS  

The Journal of infectious diseases 20160216 6

<h4>Unlabelled</h4>The ideal dengue vaccine will provide protection against all serotypes of dengue virus and will be economical and uncomplicated in its administration. To determine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to induce a suitable neutralizing antibody response, a placebo-controlled clinical trial was performed in 48 healthy adults who received 2 doses of vaccine or placebo administered 12 months apart. Evaluation of safety, vaccine virem  ...[more]

Similar Datasets

Unknown Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine.
| S-EPMC3897746 | biostudies-literature
Unknown Neutralizing antibody correlates of sequence specific dengue disease in a tetravalent dengue vaccine efficacy trial in Asia.
| S-EPMC9881745 | biostudies-literature
Unknown Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003).
| S-EPMC7990299 | biostudies-literature
Unknown Specificity and Breadth of the Neutralizing Antibody Response to a Live-Attenuated Tetravalent Dengue Vaccine.
| S-EPMC9704433 | biostudies-literature
Unknown Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America.
| S-EPMC5854020 | biostudies-literature
Unknown A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases.
| S-EPMC6279170 | biostudies-literature
Unknown Outcomes of early NIH-funded investigators: Experience of the National Institute of Allergy and Infectious Diseases.
| S-EPMC6135352 | biostudies-literature
Transcriptomics Live Attenuated Tetravalent Dengue Vaccination in Non-Human Primates
2016-05-10 | GSE72430 | GEO
Unknown Bridging Efficacy of a Tetravalent Dengue Vaccine from Children/Adolescents to Adults in Highly Endemic Countries Based on Neutralizing Antibody Response.
| S-EPMC6609170 | biostudies-literature
Unknown The National Institute of Allergy and Infectious Diseases Decision to Stop the Adaptive COVID-19 Trial: On Solid Ethical and Scientific Grounds.
| S-EPMC7250548 | biostudies-literature